Abstract
Neutropenia in oncology care usually has a disease-related or therapy-related etiology. However, for a population with a benign hematology phenomenon known as benign ethnic neutropenia (BEN) or Duffy-null associated neutrophil count (DANC), neutropenia can be unexpected or more severe during oncology care. A lack of awareness of this phenomenon and its impact can lead to actions that result in treatment delays, dose reductions, or even treatment discontinuation. Additionally, patients may be excluded from clinical trials, and neutropenia may be inaccurately graded as an adverse event or used incorrectly as a criterion for remission status due to the reference range for neutrophil counts often based on values for individuals without BEN/DANC. The population with BEN/DANC also overlaps with historically underserved groups in health care, further highlighting the urgency of raising awareness about the effects of BEN/DANC in cancer care. This presentation emphasizes the critical impact BEN/DANC plays in the neutropenia status in some oncology patients and proposes a new algorithm that advanced practitioners (APs) can use to identify BEN/DANC during initial cancer evaluation for optimization of time-sensitive and dose-sensitive therapies.
References
Andreou, A., Jayaram, J., Walker, A., Tek, C., & Williams, J. C. (2023). Re-examining the utility and validity of benign ethnic neutropenia: A narrative literature review. Schizophrenia Research, 253, 48–53. https://kdoi.org/10.1016/j.schres.2022.02.009F
Awan, Z. A., Al Amoudi, S. M., Saboor, M., & Alkhaldy, H. Y. (2021). Isolated neutropenia/benign ethnic neutropenia: A common clinical and laboratory finding in southern and western Saudi Arabia. International Journal of General Medicine, 14, 451–457. https://doi.org/10.2147/IJGM.S300690
Berliner, N. (2022). Approach to the adult with unexplained neutropenia. Newburger, P. and Rosmarin, A. G. (Eds.). UpToDate. https://www.uptodate.com/contents/approach-to-the-adult-with-unexplained-neutropenia?search=neutropenia&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1
Elhadad, D., Simon, A. J., Bronstein, Y., Yana, M., & Sharon, N. (2022). Presence of “ACKR1/DARC null” polymorphism in Arabs from Jisr az-Zarqa with benign ethnic neutropenia. Pediatric Research, 91(5), 1012–1014. https://doi.org/10.1038/s41390-021-01623-2
Forbes, W. H., Johnson, R. E., & Consolazio, F. (1941). Leukopenia in Negro workmen. The American Journal of the Medical Sciences, 201, 401–412.
Gay, K., Dulay, K., Ravindranath, Y., & Savaşan, S. (2023). Duffy-null phenotype-associated neutropenia is the most common etiology for leukopenia/neutropenia referrals to a tertiary children’s hospital. The Journal of Pediatrics, 262, 113608. https://doi.org/10.1016/j.jpeds.2023.113608
Hantel, A., Hibbs, S. P., Merz, L. E., & Abel, G. A. (2024). The Duffy Null phenotype: Addressing a source of discrimination in cancer care. The New England Journal of Medicine, 391(21), 1969–1972. https://doi.org/10.1056/NEJMp2409329
Holland, S. M., & Gallin, J. I. (2022). Disorders of granulocytes and monocytes. Loscalzo, J., Fauci, A., Kasper, D., Hauser, S., Longo, D., & Jameson, J. (Eds.), Harrison’s Principles of Internal Medicine, 21e. McGraw Hill. https://accessmedicine.mhmedical.com/content.aspx?bookid=3095§ionid=263362371
Lynce, F., Blackburn, M. J., Zhuo, R., Gallagher, C., Hahn, O. M., Abu-Khalaf, M., Mohebtash, M., Wu, T., Pohlmann, P. R., Dilawari, A., Tiwari, S. R., Chitalia, A., Warren, R., Tan, M., Shajahan-Haq, A. N., & Isaacs, C. (2021). Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer, 127(19), 3622–3630. https://doi.org/10.1002/cncr.33620
Merz, L. E., Story, C. M., Osei, M. A., Jolley, K., Ren, S., Park, H. S., Yefidoff Freedman, R., Neuberg, D., Smeland-Wagman, R., Kaufman, R. M., & Achebe, M. O. (2023). Absolute neutrophil count by Duffy status among healthy Black and African American adults. Blood Advances, 7(3), 317–320. https://doi.org/10.1182/bloodadvances.2022007679
Morrissey, S. (Host.) (2024). Audio interview with Andrew Hantel on a source of discrimination against some patients in cancer research and care practices. [Audio podcast episode published in the online posting of Dr. Andrew Hantel’s article] NEJM Interviews. The New England Journal of Medicine. https://www.nejm.org/do/10.1056/NEJMdo007809/full/
Mpofu, R., Otwombe, K., Mlisana, K., Nchabeleng, M., Allen, M., Kublin, J., McElrath, M. J., Bekker, L. G., Churchyard, G., Gray, G., & Laher, F. (2021). Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial. PloS One, 16(1), e0241708. https://doi.org/10.1371/journal.pone.0241708
Tirupati, S., Nagesh, O., & Gulati, S. (2020). Benign ethnic neutropenia and clozapine treatment protocol in Australia. (2020). Australian & New Zealand Journal of Psychiatry, 54(2), 210–211. https://doi.org/10.1177/0004867419883024
Wu, S., Powell, V., Chintoh, A., Alarabi, M., Agarwal, S. M., & Remington, G. (2024). Safety of BEN guidelines in clozapine treatment: A Canadian perspective. Schizophrenia Research, 264, 451–456. https://doi.org/10.1016/j.schres.2024.01.021
